|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG2a|
|Conjugate||Alexa Fluor® 700|
|Storage buffer||PBS with 4mg/ml BSA|
|Contains||0.1% sodium azide|
|Storage Conditions||4° C, store in dark|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||Assay-Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Flow Cytometry (Flow)||See 1 publications below|
The Alexa Fluor® 700 dye conjugate provides an excellent spectral match to the common long-wavelength excitation sources, with a high extinction coefficient.
The CD4 antigen is involved in the recognition of MHC class II molecules and is a co-receptor for HIV. CD4 is primarily expressed in a subset of T-lymphocytes, also referred to as T helper cells, but may also be expressed by other cells in the immune system, such as monocytes, macrophages, and dendritic cells. At the tissue level, CD4 expression may be detected in thymus, lymph nodes, tonsils, and spleen, and also in specific regions of the brain, gut, and other non-lymphoid tissues. CD4 functions to initiate or augment the early phase of T-cell activation through its association with the T-cell receptor complex and protein tyrosine kinase, Lck. It may also function as an important mediator of direct neuronal damage in infectious and immune-mediated diseases of the central nervous system. Multiple alternatively spliced transcripts have been identified in this gene [RefSeq, July 2017].
Analyte Specific Reagent
TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients.
MHCD0429 was used in flow cytometry to characterize therapy-induced T cell reactivity using a panel of 45 melanoma-associated CD8(+) T cell epitopes.
|Kvistborg P,Shu CJ,Heemskerk B,Fankhauser M,Thrue CA,Toebes M,van Rooij N,Linnemann C,van Buuren MM,Urbanus JH,Beltman JB,Thor Straten P,Li YF,Robbins PF,Besser MJ,Schachter J,Kenter GG,Dudley ME,Rosenberg SA,Haanen JB,Hadrup SR,Schumacher TN||Oncoimmunology (1:409)||2012|